Announced Thu, 9 Jul · 09:38 IST
Dr. Reddy's flags semaglutide supply delay due to API quality issue
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-7.7%1-day move
₹1351.10
prior close
₹1342.80
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.2-1.0-1.7-7.7-8.5-7.8-9.0-9.3-9.6————
Up moveDown movePending
AI summary
Dr. Reddy's found certain semaglutide batches out of specification due to an issue with the active pharmaceutical ingredient used in the product. The company is investigating the root cause. No impact on patient safety or existing global regulatory filings, but commercial supplies of semaglutide will be delayed until the issue is resolved. Management will host a conference call on July 9, 2026 at 16:30 IST to discuss further.
Likely market impact
Near-term revenue from semaglutide may be hit due to supply delays. No safety or regulatory risk flagged. Watch today's call for more details.